| Ytd | -43.34% | |
| 1y | -1.53% |
| Open | 2.01 | Prev Close | 1.99 | Low | 2.01 | High | 2.24 | Mkt Cap | 259.05M |
| Vol | 391.98K | Avg Vol | 868.33K | EPS | -0.48 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-06 | 50-d Avg | 1.92 | 200-d Avg | 3.30 | 1yr Est | 0.00 |
NBP News
NovaBridge Biosciences (NASDAQ:NBP) ("NovaBridge" or the "Company"), a clinical-stag
ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge”
Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026Detailed Phase 1b Data Expected to
Seasoned Biopharma leader bringing deep commercial experience to shape and inform corporate strategy
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates NovaBridge Biosciences (NASDAQ:NBP
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates NovaBridge Biosciences (NASDAQ:NBP
NovaBridge stock jumps after VIS-101 Phase 2a study shows strong vision improvement in wet age-relat
VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual
Ooma (NYSE:OOMA) shares rose 11.3% after beating Q4 earnings and revenue expectations. Other gainers
NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform com
HC Wainwright & Co. analyst Andres Y. Maldonado maintains NovaBridge Biosciences (NASDAQ:NBP)
NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform comp
NovaBridge stock was trading higher Tuesday but has since reversed and begun trading lower. NovaBrid
Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined
Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or re
